Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Seagen logo

About Seagen Stock (NASDAQ:SGEN)

Key Stats

Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
N/A
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SGEN Stock News Headlines

Pfizer raises guidance as COVID franchise drives Q3 beat
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
Franklin Biotechnology Discovery C
Pfizer: Turning The Corner (Rating Upgrade)
See More Headlines

SGEN Stock Analysis - Frequently Asked Questions

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.33. The firm's revenue for the quarter was up 27.1% on a year-over-year basis.

Seagen subsidiaries include Cascadian Therapeutics.

Based on aggregate information from My MarketBeat watchlists, some other companies that Seagen investors own include NVIDIA (NVDA), Meta Platforms (META), Intel (INTC), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE) and Qualcomm (QCOM).

Company Calendar

Last Earnings
11/01/2023
Today
9/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CIK
1060736
Employees
3,256
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($4.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$610.31 million
Net Margins
-32.61%
Pretax Margin
-32.12%
Return on Equity
-28.06%
Return on Assets
-20.92%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.67
Quick Ratio
2.12

Sales & Book Value

Annual Sales
$2.30 billion
Price / Sales
18.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.10 per share
Price / Book
15.15

Miscellaneous

Outstanding Shares
187,698,000
Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
No Data
Beta
0.32

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:SGEN) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners